Media Release 7 October 2026 • Secondary clinical endpoint results from Syntara’s interventional study of SNT-4728 in participants with isolated REM Sleep Behaviour Disorder (iRBD) complement previously reported reduction in neuroinflammation. • Converging evidence of biological...